P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study.

Autor: Terlizzi, V.1 (AUTHOR), Fevola, C.1 (AUTHOR), Presti, S.2 (AUTHOR), Castaldo, A.3 (AUTHOR), Daccò, V.4 (AUTHOR), Claut, L.4 (AUTHOR), Sepe, A.3 (AUTHOR), Majo, F.5 (AUTHOR), Casciaro, R.6 (AUTHOR), Esposito, I.7 (AUTHOR), Vitullo, P.8 (AUTHOR), Salvi, M.9 (AUTHOR), Troiani, P.10 (AUTHOR), Ficili, F.11 (AUTHOR), Parisi, G.F.2 (AUTHOR), Pantano, S.12 (AUTHOR), Costa, S.13 (AUTHOR), Leonetti, G.14 (AUTHOR), Palladino, N.15 (AUTHOR), Taccetti, G.1 (AUTHOR)
Zdroj: Journal of Cystic Fibrosis. 2024 Supplement 1, Vol. 23, pS118-S119. 2p.
Databáze: Academic Search Ultimate
Externí odkaz: